IFF — International Flavors & Fragrances Inc.

Sentiment is genuinely split rather than merely lukewarm. Bulls point to the fact that the headline Q2 2026 'miss' (revenue $1.954B, adjusted EPS $0.82) was a perimeter artifact, while the core continuing business grew 6% organically and 6% in adjusted EBITDA to $408M on pure volume, and to the announced $4.3B Food Ingredients sale plus a $2.5B repurchase authorization that includes a $500M ASR for H2 2026; Deutsche Bank and Baird have $100 targets, Oppenheimer $95. Skeptics (a Vertical Research downgrade to Hold, and value-oriented commentary with targets as low as $58) point to a spotty M&A history, residual leverage, and the question of whether buying back stock near $84 destroys rather than creates value. Price action reflects the stalemate: as of 2026-09-13 the stock was up 20.11% over six months and 6.82% over three months but down 0.29% over one month and 3.17% over the prior week.

The reported series is broken by portfolio surgery, so read it carefully. Revenue ran a stable $2.59B-$2.93B per quarter from Q3 2023 through Q1 2026, then dropped to $1.954B in Q2 2026 - that is the discontinued-operations reclassification, not a demand collapse; management reported +6% organic growth in the quarter. Gross margin is where the real signal is: it ranged 31.8%-37.3% through 2023-2025 and then jumped to 43.7% in Q2 2026 ($853M on $1.954B), consistent with shedding lower-margin Food Ingredients revenue. Operating margin is noisy and non-comparable quarter to quarter - 5.3% (Q3'23), a -$2.536B impairment quarter (Q4'23), 6.9%, 6.6%, 8.5%, 4.6%, a -$903M impairment quarter (Q1'25), 7.2%, 8.4%, 4.4%, 10.2% (Q1'26), 8.1% (Q2'26) - so the cleanest profitability read is Q2 2026 adjusted EBITDA of $408M, a ~20.9% margin. Net income is dominated by one-offs and tells you nothing: -$2.607B in Q4 2023, -$1.018B in Q1 2025, +$612M in Q2 2025 (a disposal gain). Free cash flow is genuinely inflecting: Q2 2026 FCF of $284M was the strongest Q2 in the dataset versus $155M in 2024 and $146M in 2025, lifting trailing-twelve-month FCF to $536M. The balance sheet is the most unambiguous improvement in the whole file: long-term debt fell from $9.186B at 2023-12-31 to $4.735B at 2026-06-30. Bottom line: a stable-to-modestly-improving underlying business whose reported numbers are distorted by divestitures, with the real inflection in mix and leverage rather than in the top line.

Trailing metrics are close to useless here: the TTM P/E of 76.7x and $1.133 TTM EPS are depressed by impairments, and the 5-year average P/E of 112.98x (itself computed on only 2 years of data) makes the deterministic score's 'Cheap vs. its own history' label a low-quality signal. The honest numbers: as of 2026-09-13 the stock traded at 24.3x the next-FY consensus EPS of $3.443, 1.53x book, 2.14x sales (versus a 5-year average P/S of 2.11 - essentially in line), and about 16x the midpoint of guided FY2026 continuing-operations adjusted EBITDA of $1.53B-$1.60B on a $25.5B enterprise value. Peer context: Givaudan trades around 28-30x forward earnings, Symrise around 24x, dsm-firmenich closer to 18-20x. So IFF at ~24x forward is mid-pack to slightly cheap for specialty ingredients, not a bargain, and the PEG of 1.244 is fair rather than compelling. Verdict: fairly valued, with a modest discount that only closes if execution improves.

The market is pricing in the transformation but not a full re-rating. Forward EPS of $3.443 looks like roughly 3x trailing EPS of $1.133, but almost none of that is genuine earnings power - it is the TTM base being artificially depressed by the Q1 2025 impairment, the disposal gain in Q2 2025, and the pre-close perimeter. Strip that out and you are paying ~24x for a business growing organically at roughly 6% with a 3.2% ROIC history. That means the stock needs either multiple expansion or EPS beats to work from here; simply hitting $3.44 in FY2027 and holding 24x gets you back to roughly today's price. Two things to watch: first, whether the $500M ASR and the rest of the $2.5B authorization get executed below intrinsic value (the whole buyback debate in one line), and second, whether the reset FY2026 guidance of $7.4B-$7.6B sales and $1.53B-$1.60B adjusted EBITDA proves conservative or is the first of several cuts. Given the freshly reset base, a guidance miss in Q3 2026 is a real risk, and the stock - already up 20.11% in six months as of 2026-09-13 - has limited cushion for one.

As of 2026-09-13, RSI(14) stood at 47.25 - dead neutral, neither overbought nor oversold. The price of $83.61 sat 1.77% below its 20-day SMA (roughly $85.1), 1.99% above its 50-day (roughly $82.0), and 11.45% above its 200-day (roughly $75.0). That combination - below the short average, above the intermediate and long ones - describes an intact medium-term uptrend that is consolidating after a strong run. The return profile reinforces it: +20.11% over six months and +6.82% over three months, but -0.29% over one month and -3.17% over the prior week, so momentum is cooling rather than breaking. With the 52-week range at $59.14-$89.32 and price at ~78% of it, there is no urgency to chase and no oversold signal to buy. Practically: a pullback toward the ~$82 50-day is a better entry, and a decisive break above $89.32 would confirm the next leg up; anything below $75 (the 200-day) would undercut the trend entirely.

• Interest rates and debt service: long-term debt of $4.735B as of 2026-06-30 is less than half the $9.186B carried at 2023-12-31, but refinancing costs and the relative appeal of the 2.09% dividend yield still move with the rate path, and the incoming ~$4.3B of divestiture proceeds makes the rate environment at the time of redeployment a real value driver.
• Portfolio rotation toward high-margin specialty: exiting commodity- and agriculture-exposed businesses (Food Ingredients, Pharma Solutions, soy crush) insulates IFF from crop-price cycles and shifts the mix toward IP-protected taste, scent and bioscience categories - visible in the Q2 2026 gross margin step-up to 43.7%.
• CPG customer demand and GLP-1-driven shifts in eating behavior: IFF's revenue is levered to packaged food and beverage volumes, and management is explicitly researching how weight-loss drug adoption changes formulation demand, which is both a risk to legacy categories and an opportunity for health and bioscience.
• Foreign exchange: roughly half of revenue is generated outside the US, so dollar strength translates directly into reported sales and EBITDA headwinds independent of underlying demand.
• Defensive/quality sector rotation: specialty ingredients trade as quality-defensive compounders, so a soft-landing or rate-cutting backdrop favors the group while a growth scare or a rotation into cyclicals would compress the multiple even if fundamentals hold.

• Closing of the approximately $4.3B Food Ingredients sale to CVC Capital Partners, including regulatory approval and the definitive timeline, followed by deployment of proceeds into debt paydown and repurchases.
• Execution of the $2.5B share repurchase authorization, including the $500M accelerated share repurchase slated for H2 2026 - a meaningful EPS tailwind if executed well below intrinsic value.
• Q3 2026 earnings in early November 2026: the first real checkpoint on whether the continuing-operations business can hold ~6% organic growth and expand margins against the freshly reset FY2026 guidance of $7.4B-$7.6B sales and $1.53B-$1.60B adjusted EBITDA.
• The Barclays Global Consumer Conference fireside chat on 2026-09-10, where management updated institutions on portfolio transformation and cash deployment - a near-term sentiment input that had just occurred relative to the 2026-09-13 analysis date.
• Any further portfolio pruning or a credibility-building run of consistent quarters that would justify a re-rating toward Givaudan-like multiples from the current ~24x forward earnings.

• The earnings base is unproven: FY2026 guidance was reset around continuing operations, and the $1.954B Q2 2026 revenue base is new, so the risk of further negative revisions against a freshly established bar is elevated.
• The entire equity story rests on ~6% volume-driven organic growth; any CPG destocking, private-label pressure or weakening packaged-food demand would remove the one thing supporting the current multiple.
• Capital allocation track record: after roughly $3.5B of impairments in Q4 2023 and Q1 2025 following large acquisitions, buying back stock at ~$84 is exactly the behavior value-oriented detractors cite when they argue the buyback will destroy rather than create value.
• Leverage is reduced but not gone - net debt was roughly $4.4B pre-close - and the divestiture is not yet closed, so the de-levering thesis is not yet a fact.
• Low absolute returns on capital (ROIC 3.2%, TTM net margin 2.9%) leave little room for error; the company must prove the post-close mix genuinely earns above its cost of capital rather than just reporting a higher gross margin percentage on a smaller revenue base.

IFF is a genuinely improving but not yet compelling investment at $83.61 as of 2026-09-13. The real positives are hard to dismiss - 6% volume-driven organic growth, a 43.7% gross margin in the newly reshaped portfolio, long-term debt nearly halved to $4.735B, the strongest Q2 free cash flow in three years at $284M, and a $2.5B buyback - but the stock has already re-rated 20.11% in six months, and at 24.3x next-FY EPS of $3.443 for a business with a 3.2% trailing ROIC, you are paying for the transformation to work rather than getting paid to wait. My read is roughly 9% upside to intrinsic value with real execution risk on the guidance reset and the ASR, so this is a hold-to-accumulate-on-weakness name, not a buy at this price.

Primary method: FY2027E adjusted EPS of $3.443 (FMP consensus, 6 analysts) multiplied by a 26x justified forward P/E = $89.52. The multiple is pegged to the specialty-ingredients peer set (Givaudan ~28-30x, Symrise ~24x, dsm-firmenich ~18-20x), with IFF positioned mid-range: above-peer EPS growth from the $2.5B buyback and the de-levering balance sheet, offset by a 3.2% trailing ROIC, a 2.9% trailing net margin and a mixed M&A record. Cross-check on EV/EBITDA: ~$1.65B of FY2027E adjusted EBITDA at 15.5x = $25.6B enterprise value, less ~$2.0B of post-close/net-of-buyback net debt = $23.6B equity, or about $92.4 per share on 255.3M shares. Averaging the two approaches yields roughly $91, about 8.8% above the 2026-09-13 price of $83.61 and below the $95 analyst consensus target.